On A Roll, AstraZeneca Aims For ‘Industry-Leading’ Growth From 2025

Second Antibody Drug Conjugate Is Next Milestone

 
• By Andrew McConaghie
  
Astrazeneca
New oncology drugs are expected to fuel growth to 2030 and beyond. • Source: Shutterstock

More from Business

More from Scrip